cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mohammad Saifur Rohman
Contact Email
hsj@ub.ac.id
Phone
+628973247705
Journal Mail Official
hsj@ub.ac.id
Editorial Address
Department of Cardiology and Vascular Medicine, Dr. Saiful Anwar General Hospital, 3rd Floor CVCU Jl. Jaksa Agung Suprapto No. 2, Malang, Indonesia
Location
Kota malang,
Jawa timur
INDONESIA
Heart Science Journal
Published by Universitas Brawijaya
ISSN : 27219976     EISSN : 27219984     DOI : http://dx.doi.org/10.21776/ub.hsj.2020.001.01
Core Subject : Health, Science,
Health Professions Immunology & microbiology Medicine & Pharmacology
HEART SCIENCE is the official open access journal of Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia. The journal publishes articles three times per year in January, May, and September. The journal is a peer reviewed publication and accepts articles for publication from across the world. HEART SCIENCE accepts and publishes articles in the English language only. The primary goal of this journal is to publish clinical and basic research relevant to cardiovascular medicine. The journal covers the following topics: clinical cardiology, interventional cardiology, intensive and acute cardiovascular care, vascular diseases, non-invasive cardiology, pediatric cardiology, cardiac nuclear medicine imaging, arrhythmia, cardiac prevention and rehabilitation, and cardiac surgery. Animal studies are also considered for publication in HEART SCIENCE. To serve the interest of both practicing clinicians and researchers, the journal provides platform or forum for research scholars, intellectuals, and cardiologists to reveal their views and research work for dialogue, education, and interaction to the entire world. HEART SCIENCE publishes original research, reviews, brief reports, case reports, case series, editorial, and commentary. HEART SCIENCE also publishes the special issues and abstracts of papers presented at the annual meeting of the Cardiological Society of Malang.
Arjuna Subject : Kedokteran - Cardiology and Cardiovascular Medicine
Articles 344 Documents
 31   32   33   34   35 
Renal function and potassium changes in HFrEF patients treated with ACEI vs. ARNI: A prospective cohort study among Acehnese, Indonesia Munawarah, Iffah; Heriansyah, Teuku; Syukri, Maimun; Purnawarman, Adi; Buchari
Heart Science Journal Vol. 7 No. 2 (2026): The Evolving Landscape of Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.02.10

Abstract

Background: Renin-Angiotensin-Aldosterone System (RAAS) acceleration commonly occur in Heart Failure (HF). Drugs such as Angiotensin-Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor-Neprilysin Inhibitors (ARNI) become essential part of HF treatment. Long-term consumption may impair kidney function and potassium imbalance, which could potentially limit the therapy, therefore we conducted this study to assess the effects of ACEI and ARNI on renal function and potassium level in Indonesian patients with heart failure with reduced ejection fraction (HFrEF), as no local studies exist. Method: A prospective cohort was performed in Banda Aceh, which comprise of 40 ACEI and 40 ARNI patients on standard therapy. Left ventricular ejection fraction (LVEF), serum creatinine level then converted into estimated Glomerular Filtration Rate (eGFR), and serum potassium level were measured at baseline and after 3 months into the therapy. Independent t-test was applied to compare groups. Result: Both ARNI and ACEI groups showed significant improvement in eGFR (p < 0.005). The intergroup difference was 11 mg/dL (p = 0.038) showed that ACEI had a better outcome in eGFR improvement compare with ARNI. Potassium rose slightly in both groups, with an intergroup difference of 0.082 mmol/L (p = 0.623), indicating no meaningful difference. Conclusion: Both ACEI and ARNI improved eGFR after 3 months, with a modest potassium increase.
Prognostic implications of pulmonary hypertension in heart failure preserved and reduced ejection fraction Rosyidi, Muhammad Azhar; Yogibuana, Valerinna
Heart Science Journal Vol. 7 No. 2 (2026): The Evolving Landscape of Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.02.3

Abstract

Pulmonary hypertension (PH) attributable to left heart disease (PH associated with left heart disease, PH-LHD) is the most common type of PH. PH-LHD is an important indicator of elevated morbidity and mortality in individuals with heart failure, both heart failure with preserved and reduced ejection fraction despite receive adequate therapy. Literature was sourced from major scientific databases and studies relevant to symptoms, examinations, management, and prognostic implications of PH-LHD. Pathophysiologically, PH-LHD is a gradual process that begins with increased left-heart pressure (postcapillary component), which triggers a series of biological changes in the pulmonary vasculature (precapillary component). This process ultimately places an excessive burden on the right ventricle, resulting in right ventricular dysfunction and failure, which are the main determinants of prognosis. Symptoms of PH-LHD are usually characterized by disproportionate dyspnea that is not consistent with left ventricular ejection fraction and other comorbidities. Echocardiography can noninvasively assess the probability of pulmonary hypertension in heart failure patients. A definitive diagnosis of PH-LHD requires confirmation through right heart catheterization. The most important prognostic factors are not only determined by the degree of hemodynamic severity, but also depend heavily on the degree of right ventricular dysfunction and the status of right ventricle–pulmonary artery coupling. Management of PH-LHD is through optimization of basic Guideline-Directed Medical Therapy (GDMT) to reduce mortality and morbidity.
Blood urea nitrogen as outcome predictor in acute coronary syndrome: A systematic review and meta-analysis Chandra, Graciela Natalia; Hendrawan, Fandi; Prasetyo, Hersati
Heart Science Journal Vol. 7 No. 2 (2026): The Evolving Landscape of Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.02.9

Abstract

BACKGROUND: Predicting outcomes in acute coronary syndrome (ACS) remains challenging, as established risk scores often require variables that are unavailable in low-resource healthcare settings. Blood urea nitrogen (BUN) has demonstrated prognostic value in predicting cardiovascular disease outcomes, such as heart failure and infective endocarditis. However, no meta-analysis has yet evaluated its predictive role in ACS. This study evaluated the prognostic utility of BUN for mortality and major adverse cardiac events (MACE) in ACS. METHODS: A systematic review and meta-analysis were conducted using literature from PubMed, Cochrane, and Web of Science. Risk of bias was assessed using the Risk Of Bias In Non-randomized Studies-of Exposures (ROBINS-E) tool. Pooled analysis of hazard ratios (HR) was calculated utilizing a random-effects model based on restricted maximum likelihood method. Subgroup analysis and meta-regression were performed. Sensitivity analysis was done using graphical display of study heterogeneity. RESULTS: Ten studies consisting of 7,238 participants were included. Elevated BUN was associated with heightened risk of MACE and mortality (HR: 1.05, 95% CI: 1.03–1.07, p=0.0011) and remained significant after excluding two outlier studies (HR: 1.04, 95% CI: 1.02–1.05, p=0.0002). Univariate meta-regression identified age, hypertension, and diabetes as potential covariates (p=0.112, 0.221, and 0.194). Multivariate analysis revealed no independent predictors. CONCLUSION: BUN may serve as a promising biomarker for predicting MACE and mortality in ACS, particularly in resource-limited settings. Further research is needed to compare its performance with established biomarkers or traditional scoring systems.
Improving patient outcomes : The pivotal role of guideline directed medical treatment Hasanah, Dian Yaniarti
Heart Science Journal Vol. 7 No. 2 (2026): The Evolving Landscape of Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.02.1

Abstract

Guideline directed medical therapy (GDMT) continues as the main pillar of management for heart failure with reduced ejection fraction (HFrEF). Numerous positive landmark trials and emergence of novel drugs provide strong evidence supporting the capability of GDMT in reducing cardiovascular mortality, hospitalization due to heart failure (HHF), and advancement of renal impairment. The introduction of a four-pill regimen comprising five specific pharmacological agents represents a major shift in disease-modifying care, significantly slowing symptomatic decline and improving long-term survival outcomes. Despite strong clinical recommendation, there is a huge gaps in the implementation of clinically-proven pharmacological strategies for eligible patients that further linked to relatively persistently flat mortality curves of HfrEF patients. Effective adherence to HF guidelines is often hindered by a multifaceted interplay of patient-related hurdles, clinical inertia, and systemic healthcare limitations. These challenges are further compounded by age-related complexities and multimorbidity, where concerns over pill burden and inadequate disease literacy frequently lead to suboptimal therapeutic outcomes.

Page 35 of 35 | Total Record : 344

 31   32   33   34   35 

Filter by Year

2020 2026


Reset
Filter By Issues
All Issue Vol. 7 No. 2 (2026): The Evolving Landscape of Heart Failure Vol. 7 No. 1 (2026): Accelerating Clinical Breakthroughs: The Journey from Molecular Discovery to Pa Vol. 6 No. 4 (2025): The Pursuit of Precision: Navigating Risks, Refining Diagnosis, and Securing Lo Vol. 6 No. 3 (2025): Advancements in Cardiac Imaging : Unlocking New Perspectives on the Heart Visua Vol. 6 No. 2 (2025): The Complexity in the Management of Heart Rhythm Disorder Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure Vol. 6 No. Suppl_July (2025): Supplement Issue : Indonesian Acute Coronary Syndrome Summit in Conjun Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease Vol. 5 No. 3 (2024): The Science and Art of Revascularization in Acute Coronary Syndrome Vol. 5 No. 2 (2024): Challenges in the Management of Congenital Heart and Structural Heart Diseases Vol. 5 No. 1 (2024): Inflammation and Cardiovascular Disease Vol. 4 No. 4 (2023): The Science and Art of Caring for Critically III Patients in Intensive Cardiac Vol. 4 No. 3 (2023): The Essensial Role of the Metabolic Syndrome in the Development of Cardiovascul Vol 4, No 2 (2023): Dealing with the Complexity of the Wide Spectrum of Cardiovascular Disease Vol 4, No 1 (2023): Optimizing Outcome in Acute Cardiac Care Vol. 4 No. 1 (2023): Optimizing Outcome in Acute Cardiac Care Vol 3, No 4 (2022): Prevention, Screening dan Rehabilitation : The Back Bone of Quality Care Improve Vol. 3 No. 4 (2022): Prevention, Screening dan Rehabilitation : The Back Bone of Quality Care Improv Vol. 3 No. 3 (2022): Cardiovascular Disease in Young Adulthood: Who, When, and How to Screen? Vol 3, No 3 (2022): Cardiovascular Disease in Young Adulthood: Who, When, and How to Screen? Vol 3, No 2 (2022): Improving ST-Elevation Myocardial Infraction Patients Prognosis Vol 3, No 1 (2022): Assesment and Outcome of Coronary Artery Disease in the Reperfusion Era Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease Vol 2, No 3 (2021): The Science and Art of Myocardial Revascularization Vol 2, No 2 (2021): Dealing with Vascular Disease Vol 2, No 1 (2021): How to Diagnose Heart Failure and Deal with The Treatment Complexity Vol 1, No 4 (2020): Acute Coronary Syndrome in Daily Practice : Diagnosis, Complication, and Managem Vol 1, No 3 (2020): Management of Coronary Artery Disease: From Risk Factors to The Better Long-Term Vol 1, No 2 (2020): The Assessment of Diagnostic and Treatment Modality in Heart Failure Vol 1, No 1 (2020): The Importance of Adherence to The Guidelines More Issue